Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06WNY
|
||||
| Former ID |
DNC008567
|
||||
| Drug Name |
NAVPNLRGDLQVLAQKVART
|
||||
| Indication | Discovery agent | Investigative | [528633] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C93H163N31O28
|
||||
| Canonical SMILES |
CC(C)CC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)<br />NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(C(C)C)C(=O)NC(CC(C)C<br />)C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C<br />)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C(C)O)C(=O)O)NC(=<br />O)C(CC(=O)N)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)C(C)NC(=O)C<br />(CC(=O)N)N
|
||||
| InChI |
1S/C93H163N31O28/c1-41(2)34-57(82(142)108-47(13)73(133)112-55(26-28-63(96)126)78(138)114-53(22-17-18-30-94)79(139)120-69(44(7)8)88(148)109-48(14)74(134)111-54(24-20-32-105-93(102)103)80(140)123-72(50(16)125)91(151)152)119-89(149)70(45(9)10)121-81(141)56(27-29-64(97)127)115-84(144)59(36-43(5)6)117-86(146)61(39-68(131)132)110-67(130)40-106-77(137)52(23-19-31-104-92(100)101)113-83(143)58(35-42(3)4)116-85(145)60(38-66(99)129)118-87(147)62-25-21-33-124(62)90(150)71(46(11)12)122-75(135)49(15)107-76(136)51(95)37-65(98)128/h41-62,69-72,125H,17-40,94-95H2,1-16H3,(H2,96,126)(H2,97,127)(H2,98,128)(H2,99,129)(H,106,137)(H,107,136)(H,108,142)(H,109,148)(H,110,130)(H,111,134)(H,112,133)(H,113,143)(H,114,138)(H,115,144)(H,116,145)(H,117,146)(H,118,147)(H,119,149)(H,120,139)(H,121,141)(H,122,135)(H,123,140)(H,131,132)(H,151,152)(H4,100,101,104)(H4,102,103,105)/t47-,48-,49-,50+,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,69-,70-,71-,72-/m0/s1
|
||||
| InChIKey |
BIPRZBFRCFOBDQ-KAGUSELOSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Integrin alpha-V | Target Info | Inhibitor | [528633] | |
| KEGG Pathway | Phagosome | ||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| ECM-receptor interaction | |||||
| Cell adhesion molecules (CAMs) | |||||
| Regulation of actin cytoskeleton | |||||
| Thyroid hormone signaling pathway | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| Small cell lung cancer | |||||
| Hypertrophic cardiomyopathy (HCM) | |||||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||||
| Dilated cardiomyopathy | |||||
| PANTHER Pathway | Integrin signalling pathway | ||||
| CCKR signaling map ST | |||||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | ||||
| Integrin family cell surface interactions | |||||
| Beta3 integrin cell surface interactions | |||||
| S1P3 pathway | |||||
| Osteopontin-mediated events | |||||
| Arf6 trafficking events | |||||
| Nectin adhesion pathway | |||||
| S1P1 pathway | |||||
| CXCR4-mediated signaling events | |||||
| Plexin-D1 Signaling | |||||
| Integrins in angiogenesis | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| PDGFR-beta signaling pathway | |||||
| PDGFR-alpha signaling pathway | |||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Signaling events mediated by focal adhesion kinase | |||||
| WikiPathways | Osteoblast Signaling | ||||
| Focal Adhesion | |||||
| Class I MHC mediated antigen processing & presentation | |||||
| Syndecan interactions | |||||
| Extracellular matrix organization | |||||
| Elastic fibre formation | |||||
| Primary Focal Segmental Glomerulosclerosis FSGS | |||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | |||||
| Integrin-mediated Cell Adhesion | |||||
| L1CAM interactions | |||||
| Integrin cell surface interactions | |||||
| Cell surface interactions at the vascular wall | |||||
| Osteopontin Signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.